Show me the COA or it didn't happen. The research peptide market sits at an estimated USD 52 billion globally as of 2026, and a meaningful slice of it is bunk, underdosed, or outright fake. FDA testing found up to 40% of online peptides came back with the wrong dose (FDA enforcement data, 2025). A vial labelled 5 mg might hold 3 mg. You can't tell from the label, the price, or the website. You tell from third-party HPLC and mass spec. Full stop.
This is the buyer's guide: what a real COA looks like, what purity numbers actually mean, the red flags that close the tab for you, and why you should research the compound before you ever hit checkout.
Key Takeaways
- —FDA testing (2025) flagged up to 40% of online peptides as incorrectly dosed. Underdosing is the most profitable form of fraud because nobody catches it without HPLC.
- —A G2G vendor publishes third-party HPLC + mass spec COAs with a lot number you can verify on the lab's own site. Janoshik and Finnrick are the two community-trusted independent labs.
- —≥98% HPLC is the floor for most discovery work. ≥99% is required for quantitative binding assays. Anything under 95% is bunk.
- —Use Next Pep's peptide library to lock in the mechanism, half-life, and dose range before you compare vendors.
The peptide synthesis market hit roughly USD 732 million in 2026 (Precedence Research, 2026), but the research-grade vendor space is still mostly self-policed. The vendors people call G2G all share the same cluster of traits. The grey-market ones fail in the same predictable ways.
Third-party tested or it doesn't count. A vendor running its own HPLC and posting the result as a COA is marking its own homework. Real COAs come from independent labs, Janoshik and Finnrick are the two names you'll see most in vendor-discussion threads, plus Janssen Analytical and accredited academic labs. The COA carries a report ID you can search on the lab's own site.
Lyo powder, not liquid. Quality peptides ship as lyo powder, freeze-dried to remove >99% of moisture. That step is expensive. Vendors selling pre-mixed liquid, or who skip the preservation method on the spec sheet, are cutting corners. Lyo at -20°C holds for 3 to 5 years. Liquid at room temp degrades in weeks (GenScript peptide storage guidelines).
Batch and lot specific, every time. A COA stuck to a product page that doesn't match your actual lot number is a marketing PDF, not a COA. Each shipment should ship with documentation tied to the exact lot printed on the vial.
A COA from a credible independent lab has five fields you actually care about. Each one is a yes/no.
1. HPLC purity %. HPLC separates the target peptide from everything else in the vial. The number tells you what fraction of the powder is actually the compound you ordered. Under 95% is bunk for research. ≥98% is the accepted floor for standard discovery work (Verified Peptides QA guidelines, 2025).
2. Mass spec confirmation. MS verifies the molecule's actual mass against its theoretical mass, in other words, that the sequence is the one you ordered and not a truncation or a different peptide entirely. Purity without MS confirms nothing about identity. HPLC + MS together is the dual verification floor.
3. Lot number. The lot on the COA has to match the lot stamped on the vial. Batch-to-batch variation is real, especially for longer sequences. A COA from a previous synthesis run tells you nothing about what's in your hand.
4. Test date. A COA more than six months old at the time of purchase is stale. Peptides degrade and storage between testing and shipping isn't always tight. Current COA, no exceptions.
5. Lab identity, verifiable. The lab is named, accredited, and contactable. A QR code or report ID that resolves on the lab's own server is gold standard. If you can't independently confirm the document exists, it doesn't.
Purity grades aren't marketing tiers. They map directly to what the peptide is good for in a research setting. The numbers come from HPLC and the benchmarks are well-defined (Verified Peptides, 2025).
≥99% purity is the bar for quantitative binding assays, structural biology, and any work where impurities could throw artefacts into your data. If you're measuring receptor kinetics or running cell viability at precise concentrations, 99%+ is what you want.
95–98% purity covers most discovery-phase research, standard in-vitro testing, animal work, and preliminary mechanism studies. This is what most legit research peptide vendors actually ship, and it's what most preclinical papers are working with.
Below 95% isn't research-grade. At that level, 1 in 20 molecules in the vial is something other than your target. Those impurities can confound results, cause off-target effects, or, in the case of endotoxins, light up an inflammatory response that has nothing to do with the peptide you're studying.
Most vendor problems show up before you ever click "buy". These are the patterns that show up over and over in vendors whose products fail independent testing.
1. No third-party COA, or one that won't verify. This is the single biggest filter. If the report ID doesn't resolve on the lab's own server, the COA is worthless. Janoshik and Finnrick make verification trivial, that's part of why people trust them.
2. Pricing that's too good to be real. HPLC-grade synthesis, lyo, and independent testing all cost real money. A vendor selling 5 mg of BPC-157 for $12 is either underdosing the vials or skipping QC. The economics don't math out otherwise.
3. Pre-mixed liquid (unless that's the specific product). Lyo powder is the standard for a reason: stability. A vendor shipping room-temp liquid is shipping you a degraded product that started losing potency the day it was filled.
4. Therapeutic claims and human dosing protocols on the product page. Legit research vendors don't describe products as treatments or cures. Vendors making dosing recommendations for human use are violating FDA labelling rules (FDA Final Guidance, March 2025) and are sitting in the enforcement crosshairs.
5. No physical address, no real contact info. Anonymous vendors have no accountability. No address, no phone, no named team, no reason for them to maintain quality.
6. One COA covering an entire product line. One COA = one batch of one peptide. A single PDF claiming to certify a whole catalog is a template with a logo on it.
7. Resellers playing manufacturer. Some vendors buy bulk from CN chemical suppliers and relabel domestic. Reselling itself isn't the problem, the issue is that the original synthesis standards, storage, and chain of custody are unknown. The 2025 Amino Asylum federal raid involved alleged spiking by a vendor that was reselling, not synthesising.
8. No endotoxin testing. HPLC purity doesn't catch LPS endotoxins. Vendors who only show purity, with no LAL assay, are skipping a quality check that matters for any immune-related or cell-based work.
Rather than naming specific vendors (the list goes stale fast as the market shifts and people get raided), here's the scorecard we run when adding vendors to the Next Pep library. Apply it to anyone you're considering. Each row is weighted by how well it predicts actual product quality.
| Criterion | Weight | What "pass" looks like | What "fail" looks like |
|---|---|---|---|
| Third-party COA | 25% | Independent lab name + report ID verifiable on lab's website | In-house only, no lab name, or "COA on request" |
| Purity threshold | 15% | ≥98% HPLC stated explicitly with named test method | "High purity" or "pharmaceutical grade" without a number |
| Batch-specific docs | 15% | Lot number on vial matches documentation attached to shipment | Generic COA not tied to any lot |
| Lyophilisation | 10% | "Lyophilised" or "freeze-dried" stated; arrives as dry powder | Liquid product, unspecified form, or shipped without ice pack |
| Storage guidance | 5% | Clear -20°C lyo + 4°C reconstituted guidance on label | No storage temperature specified |
| Business transparency | 10% | Physical address, named team members, direct contact method | Only a contact form, PO box, or offshore shell |
| Pricing realism | 10% | Within 30% of the market median for that compound | 40%+ below median (usually means underfilled) or absurdly high |
| Shipping & legal framing | 5% | Ships to your jurisdiction; documentation compliant with 503A or research exemption | Vague claims, "not for human consumption" disclaimer only |
| Regulatory posture | 5% | Products labelled as research compounds, no therapeutic claims | Medical claims, dosing recommendations, before/after photos |
A vendor under 70% on this scorecard, especially one that fails the COA or batch-doc rows, isn't worth the risk no matter how good the price looks. Group buys are a separate question, the same scorecard applies, just with a coordinator in the middle who should be running the same checks.
Rather than dumping a vendor list at the top level, each peptide research profile on Next Pep carries a per-compound vendor section, vendors we've run through this scorecard. For example:
The structure is deliberate: compound-specific data sits next to vendor availability so you make the buy decision with mechanism and pharmacokinetics in front of you, not in isolation.
The legal picture shifted hard in early 2026. In February, HHS Secretary Robert F. Kennedy Jr. announced that roughly 14 of the 19 peptides previously on the FDA's Category 2 restricted list would move back to Category 1, restoring access through licensed compounding pharmacies with a physician's prescription (Elite NP, 2026).
That reclassification is real, but it doesn't change direct online buying. What it does mean: some peptides previously cut off from compounding pharmacies are accessible again, but you still need a licensed prescriber and a 503A-compliant compounding pharmacy to get the compounded version.
Research peptides sold direct online sit in the gray market. Possession for personal research isn't a scheduled offence in the US, but vendors marketing therapeutic claims, selling to individuals without institutional cover, or shipping without compliant labelling are dealing with active FDA enforcement. The March 2025 Final Guidance set new rules for research-grade peptide labelling and institutional verification (Frier Levitt, 2025).
The practical version: access exists, but how you access matters as much as whether you can.
Before you spend a dollar on any peptide, knowing what you're buying is the highest-leverage step you can take. That means mechanism, half-life, the actual evidence base, and how the compound stacks up against alternatives. That's what Next Pep's peptide library is built for.
The library covers every major research peptide with clinical-grade data: mechanism, amino acid sequence, molecular formula, CAS number, pharmacokinetics, dosing range, and primary PubMed citations, all cross-referenced. You're not relying on a vendor's product page, which has an obvious conflict of interest.
If you're choosing between BPC-157 and TB-500, or trying to figure out whether sermorelin or CJC-1295 makes more sense for what you want to do, the comparison tool puts up to four peptides side by side across pharmacokinetics, chemistry, and dosing.
Once you've picked a compound and need to work out reco volume, the dosing calculator converts vial mg to draw volume and insulin syringe units, so you're not guessing on the math before you've even pinned anything.
Research first. Purchase second. That sequence matters.
People showing up to the peptide market for the first time usually have a specific compound in mind, something they read about in a case report, heard on a clinical podcast, or saw in a peer-reviewed paper. Below are the most-searched research peptides on Next Pep, with links to the full profiles and compound-specific buyer guides.
BPC-157, A 15-amino-acid gastric peptide with the deepest preclinical literature of any research peptide. Mechanisms hit VEGFR2–eNOS angiogenesis, FAK-paxillin cell migration, and GHR upregulation. FDA Category 2 status restricts compounding. → Where to Buy BPC-157
TB-500, Thymosin beta-4 fragment (residues 17–23), studied for actin regulation, anti-inflammatory cytokine modulation, and cardiac tissue remodelling. No completed human trials. WADA banned since 2011. Molecular weight ~889 Da, not 4,963 Da (that's full-length TB4). → Where to Buy TB-500
Ipamorelin, Selective GHRP that binds GHS-R1a without driving up ACTH or cortisol. Most commonly stacked with CJC-1295 (the CJC + ipa stack). Both compounds were pulled from FDA Category 2 in September 2024 and are expected to land back in Category 1 under the current reclassification. → Where to Buy Ipamorelin and CJC-1295
Tirzepatide, Dual GIP/GLP-1 receptor agonist and FDA-approved drug (Mounjaro for T2D, Zepbound for obesity). The SURMOUNT-5 head-to-head showed 20.2% weight loss vs 13.7% for sema at 72 weeks. Prescription required. → Where to Buy Tirzepatide
Sermorelin, A 29-amino acid GHRH analogue that pushes the pituitary to make GH naturally. FDA-approved 1997, withdrawn 2008 for manufacturing reasons (not safety). Category 1 compoundable with a physician prescription. Vittone 1997 showed 117% IGF-1 elevation at 20 weeks. → Where to Buy Sermorelin
PT-141 (Bremelanotide), The only FDA-approved peptide for sexual dysfunction (Vyleesi, approved 2019 for HSDD in premenopausal women). MC4R central mechanism, completely different from PDE5 inhibitors. Off-label use in males is supported by Phase II data. → Where to Buy PT-141
GHK-Cu (Copper Peptide), Endogenous tripeptide with a 28% collagen increase shown in a clinical RCT. Category 2 for injectable compounding, Category 1 for topical formulations via 503A pharmacies. Three access routes depending on application. → Where to Buy GHK-Cu
Semaglutide, FDA-approved GLP-1 receptor agonist (Ozempic, Wegovy). The FDA shortage closed in February 2026 and compounded sema enforcement kicked in April/May 2026. Branded access runs $935–$1,350/month depending on indication. → Where to Buy Semaglutide
Use Next Pep's comparison tool to put any of these side by side, mechanism, pharmacokinetics, and dosing data in one view, before you start vetting any vendor.
In-depth research profiles for the peptides most-asked about in the buyer guide:
A real COA includes HPLC purity (≥98% minimum for research use), mass spec confirmation of molecular identity, the specific lot or batch number that matches your vial, the test date (within six months), and a named independent lab with a verifiable report ID. In-house COAs from the vendor itself carry zero independent value.
The price gap is real cost, real synthesis purity, real lyo, real third-party testing. HPLC-grade synthesis at ≥99%, certified lyo, and independent lab work all add cost. Vendors priced way under market are skipping at least one of those steps. FDA testing found up to 40% of online peptides are underdosed, that's the cheapest and most common form of fraud.
For personal research, possession of most research peptides isn't a scheduled offence in the US. But vendors marketing therapeutic claims or shipping without compliant labelling are dealing with active FDA enforcement under the March 2025 Final Guidance. Compounded peptides via a 503A pharmacy with a physician's script is the only route with formal regulatory oversight on quality.
Lyophilisation is freeze-drying, removing >99% of moisture from the peptide solution to leave a stable dry powder. Lyo peptides at -20°C hold for 3 to 5 years (GenScript, 2025). Liquid peptides degrade fast. If a vendor doesn't specify lyophilisation as their preservation method, assume the shelf stability is shot.
Use Next Pep's free comparison tool to put up to four peptides side by side, mechanism, half-life, dosing data, and molecular chemistry in one view. Combined with the peptide library for in-depth profiles and the dosing calculator for reco math, you've got the research foundation to make a real decision before any purchase.
This article is for research and educational purposes only. Research peptides are not approved for human therapeutic use.
Research Disclaimer. All content on Next Pep is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Consult a licensed healthcare professional before considering any peptide protocol.
CJC-1295 with DAC has a 6-8 DAY half-life; Modified GRF (1-29) clears in ~30 minutes. Same modified GHRH(1-29) backbone, one bolt-on linker, ~1,000x PK difference.
TB-500 is a 7-aa fragment of thymosin beta-4 (43 aa, ~4,963 Da), not the full protein. Cross-COA review: ~67% of "TB-500" vials are actually full Tβ4.